Bacteriostatic Antibiotics MarketRegional Analysis
North America BacteriostaticAntibiotics Market is expected to hold a dominant position in the globalBacteriostatic Antibiotics Market and account for largest market share over theforecast period, owing to presence of key players and approval and launch ofnovel bacteriostatic antibiotics drugs by them in the region.
For instance, in August 2018,Tetraphase Pharmaceuticals, Inc., a Massachusetts, U.S-based biopharmaceuticalcompany, received the U.S. Food and Drug Administration (FDA) approval for itsnovel bacteriostatic antibiotics namely XERAVA (eravacycline) for the treatmentof complicated intra-abdominal infections (cIAI)
Antibiotics are naturallyoccurring or artificially produced substances, which are widely used in thetreatment of bacterial diseases. Antibiotics works by killing bacteria(bactericidal effect) or by inhibiting their growth (bacteriostatic effect).Although bacteriostatic antibiotics prevent bacterial growth and reproduction,it does not necessarily kill them.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2307
Bacteriostatic Antibiotics MarketDrivers
Global bacteriostatic antibioticsmarket is expected to witness a significant growth over the forecast period,owing to recent approval and launch of novel bacteriostatic antibioticsproducts in the market.
For instance, in September 2018,Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company dedicated todevelopment, manufacturing, and commercialization of novel antibiotics fortreat life-threatening multidrug-resistant (MDR) infections received EuropeanCommission (EC) marketing authorization for its novel bacteriostatic antibioticnamely XERAVA (eravacycline) injection, which is indicated for the treatment ofcomplicated intra-abdominal infections (cIAI) in adults in the European Union.XERAVA (Eravacycline) is a fluorocycline antibacterial within the tetracyclineclass of antibacterial drugs, it is bacteriostatic against gram-positivebacteria (e.g., Staphylococcus aureus and Enterococcus faecalis)
Furthermore, high prevalence ofbacterial and infectious disease is expected to propel demand forbacteriostatic antibiotics, in turn driving global bacteriostatic antibioticsmarket growth.
For instance, according to thedata published by Centers of Disease Control and Prevention (CDC), in 2016, anestimated 9,272 people suffered from tuberculosis, 53,850 from salmonella, and36,429 from Lyme disease in the U.S.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/bacteriostatic-antibiotics-market-2307
Bacteriostatic Antibiotics MarketRestraint
Some side effect associated withbacteriostatic antibiotics may lower adoption of these drugs and hinder globalbacteriostatic antibiotics market growth. For instance, chloramphenicol, a typeof bacteriostatic antibiotic have severe side effects such as bone marrowsuppression, severe allergic reactions, and can also lead to mental disorders.
Furthermore, presence ofbactericidal antibiotics, which is an alternative of bacteriostatic antibioticsmay create an internal threat of substitute and hinder global bacteriostaticantibiotics market growth.
Bacteriostatic Antibiotics MarketKey Players
Key players operating in globalBacteriostatic Antibiotics Market include Tetraphase Pharmaceuticals, Inc.,Allergan Plc., Pfizer Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd.,Hikma Pharmaceuticals Plc., Akorn Inc., and Others
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2307
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
